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Feifei Yu1†, Zhichao Jin1†, Hong Jiang1†, Chun Xiang1†, Jianyuan Tang2, Tuo Li3 and Jia He1*Abstract
Background: We conducted a dose–response meta-analysis of prospective studies to summarize evidence of the
association between tea consumption and the risk of breast, colorectal, liver, prostate, and stomach cancer.
Methods: We searched PubMed and two other databases. Prospective studies that reported risk ratios (RRs) with
95% confidence intervals (CIs) of cancer risk for ≥3 categories of tea consumption were included. We estimated an
overall RR with 95% CI for an increase of three cups/day of tea consumption, and, usingrestricted cubic splines, we
examined a nonlinear association between tea consumption and cancer risk.
Results: Forty-one prospective studies, with a total of 3,027,702 participants and 49,103 cancer cases, were
included. From the pooled overall RRs, no inverse association between tea consumption and risk of five major
cancers was observed. However, subgroup analysis showed that increase in consumption of three cups of black tea
per day was a significant risk factor for breast cancer (RR, 1.18; 95% CI, 1.05-1.32).
Conclusion: Ourresults did not show a protective role of tea in five major cancers. Additional large prospective
cohort studies are needed to make a convincing case for associations.
Keywords: Tea consumption, Dose–response, Meta-analysis, CancerBackground
Tea is a popular beverage consumed worldwide, generally
in the forms of black and green tea. Tea is produced from
the leaves of the Camellia sinensis plant through several
processes. Black tea is the main tea beverage in the United
States, Europe, and Western Asia, while green tea is more
popular in China, Japan, and Korea [1]. Extensive labora-
tory studies using multiple animal models have suggested
that tea and tea polyphenols might have an inverse associ-
ation with cancer through its apoptosis-inducing, anti-
mutagenic, and antioxidant properties [2,3].
In some recent reviews, researchers have suggested that
green tea, which contains abundant polyphenols and cate-
chins, specifically epigallocatechin-3-gallate (EGCG) 5,
might have a protective effect against cancers. Using mul-
tiple approaches, studies have shown that polyphenols,* Correspondence: hejia63@yeah.net
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unless otherwise stated.theaflavins (TF) and thearubigins (TR) in black tea might
possess chemopreventive properties. However, most of the
evidence showing a protective effect of tea on cancer has
been generated in animal experiments but has not been
demonstrated in human trials [4,5].
The World Cancer Research Fund report of 2007 con-
cluded that the evidence for associations between the
consumption of tea and risk of some major cancers was
still limited and inconsistent [6]. The results from a few
clinical trials and epidemiological studies also indicated
that the preventive effect of tea or its extract on cancer
is controversial. In a recent clinical trial evaluating the
efficacy of green tea extract (GTE) on prostate cancer, it
was found that the GTE had minimal clinical activity
[7,8]. However, another Phase II clinical trial suggested
that higher doses of GTE might improve the short-term
outcome in patients with a higher risk of oral premalig-
nant lesions [9]. In a cohort study conducted in the
USA, tea consumption was found to have no inverse as-
sociation with colorectal cancer, and the hazard ratioThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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[10]. However, in another cohort study conducted in
China, results showed that regular green tea consump-
tion was associated with a reduced risk of colorectal can-
cer in smokers [11]. Some recent systematic reviews
have revealed conflicting results between meta-analyses
with prospective studies and those with retrospective
studies [12-16].
Previous meta-analyses mainly focused on the relation-
ship between the highest tea consumption level and either
the lowest tea consumption level or non-drinkers. However,
the range of tea consumption and the cut-offs for the cat-
egories differed between studies. Another drawback of the
previous meta-analyses is the inclusion of retrospective
case–control studies, which were sensitive to confounding
variables and bias, especially recall bias. To quantitatively
assess the relationship between tea consumption and risk
of five major cancers, we conducted a systematic review
and dose–response meta-analysis with prospective studies.
The five major cancers we studied were liver, stomach,
breast, prostate, and colorectal cancer.
Methods
Literature search
We performed a systematic literature search in PubMed,
Embase, and Cochrane Library with a combination of
the following terms: tea AND (breast OR prostate OR
stomach OR gastric OR colorectal OR colorectum OR
rectal OR rectum OR colon OR large bowel OR liver
OR hepatic OR hepatoma) AND (cancer OR cancers OR
carcinoma OR carcinomas OR neoplasm OR neo-
plasms). No language restrictions were imposed. Refer-
ence lists of the identified publications were also
reviewed for inclusion/exclusion. We also searched the
conference abstract on the website of American Society
of Clinical Oncology (ASCO) annual meeting from 2004
to 2013. Two reviewers (FY and CX) independently se-
lected studies based on the titles and abstracts of the re-
trieved studies. Studies were included if they met the
following criteria: (1) a prospective study assessing the
association between tea consumption and at least one of
the five selected cancers (breast, stomach, colorectal,
liver and prostate cancer); (2) a study considering at
least three levels of tea consumption and providing a
sample size for cases and non-cases in each exposure
category [17]; and (3) a study reporting the relative risks
(RRs) of different dose categories with 95% confidence
intervals (95% CIs) adjusted for sex, age, or other factors.
We excluded retrospective case–control studies because
of their inherent limitations, especially recall bias. How-
ever, nested case–control studies and case-cohort studies
were included in our meta-analysis because the at-risk
study populations in each of the exposure categories are
derived from cohort studies and diet exposure wouldhave been investigated years before the onset of cancer,
which would technically eliminate recall bias. We also
excluded studies that reported total tea consumption on
monthly, weekly, or daily basis, but did not provide data
on number of cups or times per month, week or day.
One study assessing breast cancer risk was excluded be-
cause we could not extract data stratified by sex in both
exposed and unexposed groups [18]. Another study was
excluded because it reported stomach cancer risk based
on iced tea and hot tea consumption, but no other study
provided such data [19].
Data extraction
Data extraction was performed according to the MOOSE
(meta-analysis of observation studies in epidemiology)
guidelines [20] (see the Additional file 1) by two reviewers
(FY and CX), and verified independently for accuracy by a
third reviewer (ZJ). Discrepancies were discussed with a
fourth reviewer (JH) to reach a consensus. For each in-
cluded study, the following data was extracted: the title and
author of the study, publication year, study population,
study location, sample size, proportion of males, median of
follow-up time, the type of consumed tea, covariates con-
trolled for by matching or multivariable analysis, the num-
bers of cases/non-cases, total person-years, relative risk
(RR) of the different exposure categories and the corre-
sponding 95% confidence intervals (95% CIs), response rate,
and how exposure were assessed. For studies that reported
several multivariable adjusted RRs, we selected the effect
estimate that adjusted for the maximum potential con-
founders. The quality of the included studies was assessed
according to the 9-star Newcastle-Ottawa Scale (NOS) [21]
by two investigators (FY and HJ).
Statistical analysis
We performed a two-stage dose–response meta-analysis to
examine the relationship between tea consumption and five
major cancer risks. First, we synthesized the RRs across cat-
egories of tea consumption in each study [22,23]. Because
the absolute risk of cancer is low, the odds ratios (ORs) in
nested case–control studies approximated the RRs [24].
Pooling of RRs from each study requires the exposure levels
and distribution of cases and person-years or non-cases in
each category of tea consumption. However, not all studies
reported the distributions of cases and person-years or
non-cases for exposure categories. Nine studies did not re-
port individuals or person-years for each category and in-
stead reported the total sample size [10,11,25-31]. We
estimated the distribution of cases for each category in such
studies by using the methods described by Aune [32]. To
assess exposure levels, we converted all measures into cups
per day and defined 125 mL of tea as one cup regardless of
tea type unless it was well established in a specific study
population or a geographical area. If the study reported tea
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one cup. As some Chinese studies reported the amount of
tea leaves consumed as the measure of tea consumption,
we regarded consumption of 150 g of tea leaves per month
as one cup per day; this allowed us to universalize all of the
included studies in a single standard unit [33].
If a study did not report the median of the exposure
category, we assigned the level of tea consumption to
categories based on the calculated midpoint of tea con-
sumption. When the highest category was open-ended,
we assumed the dose as 1.2 times the lowest bound of
this category [17]. In studies reporting tea consumption
by cups per month or cups per week, we redefined these
exposure categories as cups per day by multiplying with
1/30 or 1/7, respectively. Subsequently, we estimated the
overall RR by combining the RRs derived from the first
step. A fixed effect model was used if there was no evi-
dence of heterogeneity; otherwise a random effect model
was adopted [34,35]. Forest plots were used to visually
assess the RR estimates and corresponding 95% CIs. We
also tested the nonlinear relationship between tea con-
sumption and cancer risk by modeling tea consumption
levels by using restricted cubic splines with 3 knots at
fixed percentiles (10%, 50%, and 90%) of the distribution
as described by Larsson and Orsini [36,37]. A P value
for nonlinearity was calculated by testing the null hy-
pothesis that the coefficient of the second and third
spline was equal to zero.
Eight studies on colorectal cancer [10,26,27,31,38-41]
and three studies on stomach cancer [27,42,43] reported
cancer risk by sex. Ten studies reported colorectal
cancer risk stratified as colon or rectal cancer
[10,18,26,27,38-41,44,45]. One study reported colon can-
cer risk as a distal or proximal cancer [38]. The study by
Inoue et al. pooled data from six cohort Japanese studies
that studied the relationship between tea consumption
and stomach cancer [43]. Results from these studies were
first pooled by using a fixed model and then included in
the overall risk estimate. The χ2 test and I2 statistic were
used to explore the heterogeneity among studies [46].
The Egger’s regression test, Begg’s rank correlation test,
and visual inspection of a funnel plot were performed to
assess publication bias [47,48]. As a rule of thumb, tests
for asymmetry should be used only when there are at
least 10 studies included in a meta-analysis [35]. We con-
ducted subgroup analyses stratified by sex, tea types, and
geographic regions. For breast cancer, we also performed
a subgroup analysis stratified by menopausal status. We
performed a sensitivity analysis in which one study at a
time was removed and the rest analyzed to evaluate
whether the results could have been affected markedly by
a single study. To detect whether different assessment
ways may bias the results, further subgroup analyses
were performed by excluding studies that reported teaconsumption by frequency (times/servings) [18,42,49-52],
weight of tea leaves (grams) [11,27,33], or volume (mL)
[53,54], rather than cups.
We used Stata (Version 12.0; Stata Corp, College Station,
TX) for all analyses and all statistical tests were two-sided.
P < 0.05 was considered statistically significant.
Result
Study characteristics
As of December 28, 2013, 1,881 records were retrieved
by using our search strategy. After reviewing the titles
and abstracts, we excluded 1,668 articles and 213 articles
were further evaluated by reviewing the full texts. Fi-
nally, we identified 41 articles assessing tea consumption
and cancer risk, which satisfied the inclusion criteria for
our meta-analysis. A flow diagram of study selection is
provided as Figure 1. Among the 41 articles, 15 assessed
the relationship between tea drinking and the incidence
for breast cancer [25,33,41,49,51,54-63], 15 for colorectal
cancer [10,11,18,26-29,31,38-41,44,45,59], 4 for liver can-
cer [18,27,64,65], 7 for prostate cancer [30,50,53,66-69],
and 5 for stomach cancer [27,42,43,52,59]. The 41 arti-
cles included had 3,027,702 participants and 49,103 can-
cer cases. The cancer cases included 20,500 breast
cancer patients; 16,202 colorectal cancer patients; 882
liver cancer patients; 4,698 prostate cancer patients; and
6,821 stomach cancer patients. Most of the included
studies awarded more than 7 stars according to the
Newcastle-Ottawa Scale and were identified as high
quality. The general characteristics of the included stud-
ies are presented in Table 1.
Tea consumption and cancers
The associations between tea consumption and the risk
of major cancers are shown in Figures 2, 3, 4, 5 and 6.
For breast cancer, the overall RR for three cups incre-
ment per day of tea consumption was 1.02 (95% CI, 0.98
to 1.05) with mild heterogeneity among studies (P = 0.22,
I2 = 21.2%). For colorectal cancer, the pooled RR for
three cups increment per day was 0.98 (95% CI, 0.93 to
1.03) with mild heterogeneity (P = 0.29, I2 = 15.0%). For
liver cancer, the overall RR for three cups increment per
day was 0.91 (95% CI, 0.74-1.12) with moderate hetero-
geneity (P = 0.10, I2 = 52.5%). For prostate cancer, the
overall RR for three cups increment per day was 1.02
(95% CI, 0.96 to 1.09) with moderate heterogeneity (P =
0.14, I2 = 37.8%). For stomach cancer, the overall RR for
three cups increment per day was 0.98 (95% CI, 0.93-
1.03) with moderate heterogeneity (P = 0.15, I2 = 40.6%).
As shown by Figure 7 and the P-value for nonlinearity,
we found no evidence of nonlinear relationships between
tea consumption and risk of cancers.
In the subgroup analysis, we pooled the studies into
groups by sex, tea type, geographic region, and menopausal
Figure 1 Summary of article selection process.
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We found that three cups of black tea consumption incre-
ment per day may be a risk factor for breast cancer (RR,
1.18; 95% CI, 1.05-1.32). The result of the subgroup analysis
of stomach cancer indicated that tea consumption was a
preventive factor (RR, 0.88; 95% CI, 0.80-0.98) in women.
However, only three studies were included in this
subgroup.
A sensitivity analysis omitting one study at a time and
calculating the pooled RRs for the remainder of the studies
suggested that no single study dramatically influenced the
pooled RRs (results are not shown). After removing the
studies that did not report tea consumption as cups per
day, the results did not change significantly. On excluding a
study by Inoue et al. [43], which had a significantly larger
sample size in comparison with other included studies, no
significant differences were observed.Egger’s regression test and Begg’s rank correlation test
showed no significant asymmetry of the funnel plot for
breast (P = 0.59 and P = 0.60, respectively) and colorectal
cancer (P = 0.59 and P = 0.73, respectively), indicating no
evidence of substantial publication bias (Figure 8). For
the other three types of cancer, we did not perform an
analysis for publication bias because of limited numbers
of included studies (no more than ten).
Discussion
The findings from our meta-analysis reveal no appre-
ciable association between tea consumption and the
relative risk of liver, stomach, breast, prostate, or colo-
rectal cancers. The risk differences were all near zero for
the five major cancers with an increase in tea consump-
tion of three cups per day (approximately 375 mL per
day). Subgroup analyses, stratified by sex, geographic
Table 1 Main characteristics of the studies on tea consumption and five selected cancer included in the meta-analysis











France Cohort Population based (E3N study) Tea (unclear) 67703 2868 40-65 11 0 (0)
Iwasaki et al.
2010 [60]
Japan Cohort Population based (JPHC study) Green tea &
Black tea
53793 845 40-69 13.6 0 (0)
Dai et al.
2010 [33]
China Cohort Population based (SWHS study) Green tea 72861 614 40-70 7.3 0 (0)
Boggs et al.
2010 [56]
USA Cohort Population based (BWHS study) Tea (unclear) 52062 1268 21-69 12 0 (0)
Pathy et al.
2010 [55]
Dutch Cohort Population based (EPIC-NL study) Tea (unclear) 27323 681 20-70 9.6 0 (0)
Larsson et al.
2009 [61]
Sweden Cohort Population based (Swedish Mammography Cohort) Black tea 66651 2952 40-76 17.4 0 (0)
Ishitani et al.
2008 [25]
USA Cohort Population based (Women’s Health Study) Tea (unclear) 38432 1188 >45 10 0 (0)
Ganmaa et al.
2008 [58]
USA Cohort Registered nurses (Nurses’ Health Study) Tea (unclear) 85987 5272 30-55 22 0 (0)
Hirvonen et al.
2006 [54]
France Cohort Double-blind placebo-controlled primary-prevention
trial (SU.VI.MAX Study)
Tea (unclear) 4396 95 35-60 6.6 0 (0)
Adebamowo
et al. 2005 [49]
USA Cohort Registered nurses (Nurses’ Health Study II) Tea (unclear) 90638 710 25-46 4 0 (0)
Suzuki et al.
2004 [63]
Japan Cohort Population based Green tea 35004 222 40-64 7-9 0 (0)
Michels et al.
2002 [62]
Sweden Cohort Population based (Swedish Mammography Screening
Cohort)
Tea (unclear) 59036 1271 40-76 10.8 0 (0)
Key et al.
1999 [51]
Japan Cohort Hiroshima or Nagasaki bombings survivor (LSS study) Green tea &
Black tea





USA Cohort Population based (Iowa Women’sHealth Study) Non-herbal
tea
35369 1602 55-69 8 0 (0)
Goldbohm
et al. 1996 [59]
Netherlands Case-cohort Population based (Netherlands Cohort Study on Diet
and Cancer)
Black tea 1376 507 55-69 4.3 0 (0)
Colorectal Cancer
Dominianni
et al. 2013 [29]
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Simons et al.
2010 [38]












USA Cohort Registered nurses and health professionals (NHS and
HPFS)




Japan Cohort Population based Green tea 26311 269 40-64 8-9 -
Su et al.
2002 [28]
USA Cohort Population based (NHEFS study) Tea (unclear) 10011 219 25-74 20 -
Terry et al.
2001 [45]
Sweden Cohort Population based (The Swedish Mammography
Screening Cohort)
Black tea 61463 460 40-76 9.6 0 (0)
Nagano et al.
2001 [18]




Finnish RCT Randomized, double-blind, placebo-controlled
prevention trial (ATBC Study)




USA Cohort Population based (Iowa Women’s Health Study) Non-herbal
tea
35369 474 55-69 8 0 (0)
Goldbohm
et al. 1996 [59]
Netherlands Case-cohort Population based (Netherlands Cohort Study on Diet
and Cancer)
Black tea 2929 564 55-69 4.3 0 (0)
Nechuta et al.
2012 [27]




China Cohort Population based (Shanghai Women’s Health Study) Tea (any) 69310 134 40-70 11 0 (0)
Ui et al.
2009 [65]




Japan Cohort Population based (Japan Public Health Center-Based
Prospective Study Cohort II)













Singepore Cohort Population based (Singapore Chinese Health Study) Green tea &
Black tea




Canada Cohort Employed men and women
(Collaborative Cohort Study)
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Kurahashi et al.
2008 [67]








Japan Cohort Atomic-Bomb Survivors (LSS Study) Green tea &
Black tea









China Cohort Population based (Shanghai Women’s Health Study) Tea (any) 69310 293 40-70 11 0 (0)
Inoue et al.
2009 [43]
Japan Cohort Pooled Study (JPHC-I, JPHC-II, JACC, MIYAGI,3-pref
MIYAGI,3-pref AICHI)








Japan Cohort Population based Green tea 11907 108 46.4 14.8 5610
(47.1)
Goldbohm
et al. 1996 [59]
Netherlands Case-cohort Population based (Netherlands Cohort Study on Diet
and Cancer)
Black tea 2929 182 55-69 4.3 0 (0)







UK Self-administered FFQ Total energy intake, ever use of oral contraceptives, age at menarche, age at menopause, number of children, age at
first pregnancy, history of breast cancer in the family and years of schooling, current use of postmenopausal hormone




>80% Self-administered FFQ Age, area, age at menarche, menopausal status at baseline, number of births, age at first birth, height, BMI, alcohol
intake, smoking status, leisure time physical activity, daily physical activity, exogenous hormone use, family history of






(frequency of tea consumption)
Age, educational achievement, income, family history of breast cancer, history of fibro adenoma, body mass index,
waist-to-hip ratio, physically active, smoking status, alcohol consumption status, passive smoking status, ginseng intake,
age at menarche, age at first live birth, menopausal status, age at menopause, use of hormone replacement therapy,




>80% Self-administered FFQ Age, energy intake, age at menarche, BMI at age 18, family history of breast cancer, education, geographic region,
parity, age at first birth, oral contraceptive use, menopausal status, age at menopause, female hormone use, vigorous




UK Self-administered FFQ Propensity score (based on age, smoking status, educational status, BMI, alcohol intake, energy intake, energy adjusted
saturated fat intake, energy adjusted fiber intake, coffee intake, physical activity level, ever use of oral contraceptives,
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Larsson et al.
2009 [61]
74% Self-administered FFQ Age, education, body mass index, height, parity, age at first birth, age at menarche, age at menopause, use of oral





100% Self-administered FFQ Age, randomized treatment assignment, body mass index, physical activity, total energy intake, alcohol intake, multivitamin
use, age at menopause, age at menarche, age at first pregnancy lasting ≥6 months, number of pregnancies lasting
≥6 months, menopausal status, postmenopausal hormone use, prior hysterectomy, prior bilateral oophorectomy, smoking




90% Self-administered FFQ Age months, smoking status, body mass index, physical activity, height, alcohol intake, family history of breast
cancer in mother or a sister, history of benign breast disease, menopausal status, age at menopause, use of
hormone therapy, age at menarche, parity and age at first birth, weight change after18 and duration of




UK Self-administered 24 h dietary
record
Age, smoking, number of children, use of oral contraception, family history of breast cancer, and menopausal status 7
Adebamowo
et al. 2005 [49]
>90% Self-administered FFQ Age at menarche, parity, age at first birth, family history of breast cancer in mother and/or sister, history of benign
breast disease, oral contraceptive use, alcohol consumption, energy intake, current body mass index, height,




94% Self-administered FFQ Age, types of health insurance, age at menarche, menopausal status, age at first birth, parity, mother’s history of




76% Self-administered FFQ Age, family history of breast cancer, height, body mass index, education, parity, age at first birth, alcohol




53.4% Self-administered FFQ Attained age, calendar period, city, age at time of bombing and radiation dose 6
Zheng et al.
1996 [41]
42.3% Self-administered FFQ Age, education, smoking status, pack-years of smoking, physical activity, all fruit and vegetable Intake, waist/hip
ratio, and family history of cancer, age at menarche, age at menopause, age at first pregnancy
7
Goldbohm
et al. 1996 [59]
UK Self-administered FFQ Benign breast disease, history of breast cancer in mother and sisters, age at menarche, age at menopause, use of





et al. 2013 [29]
78% Self-administered FFQ Age, gender, race, family history of colorectal cancer, education, body mass index, physical activity, smoking status,
NSAID intake, history of diabetes, number of colorectal examinations up to 3 years before the start of study,




UK Self-administered FFQ Age, sex, race, education, smoking status, time since quitting for former smokers, smoking dose, ever smoke a pipe
or cigar, diabetes, colorectal screening, family history of colorectal cancer, regular
non-steroidal anti-inflammatory drug use, marital status, BMI, frequency of vigorous physical activity, calories, fruit





(frequency of tea consumption)
Age, education, cigarette smoking, pack-years of cigarette smoking, alcohol consumption, regular exercise, body




UK Self-administered FFQ Age, family history of CRC, non-occupational physical activity, smoking status, educational level, body mass index,





79% Self-administered FFQ BMI, smoking status, alcohol drinking, family history of colorectal cancer, physical activity, and intake of green
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Oba et al.
2006 [31]





91.7% Self-administered FFQ Sex, age, family history of colorectal cancer, cigarette smoking, alcohol consumption, body mass index, consumption
of black tea, and coffee. Cohort1 adjusted for consumption of meat, green-yellow vegetables, other vegetables,
and fruits. Cohort2 adjusted for consumption of beef, pork, ham, chicken, liver, spinach, carrot or pumpkin, tomato,




100% and 96% Self-administered FFQ Age, family history of colorectal cancer, history of sigmoidoscopy, height, body mass index, pack-years of smoking,
physical activity, aspirin use, vitamin supplement intake, alcohol consumption, red meat consumption, total caloric





(24 h food recall)





98% Self-administered FFQ Age in 5-yr age groups, body mass index (quartiles), education level (3 categories), quartiles of total calories, red





72% Self-administered FFQ City, age, gender, radiation exposure, smoking status, alcohol drinking, body mass index, education level, calendar time 6
Hartman et al.
1998 [40]
_ Self-administered FFQ Age, intervention group, calcium, occupational physical activity, and BMI. 7
Zheng et al.
1996 [41]
42.3% Self-administered FFQ Age, education, smoking status, pack-years of smoking, physical activity, all fruit and vegetable Intake, waist/hip
ratio, and family history of cancer
7
Goldbohm
et al. 1996 [59]
96% Self-administered FFQ Benign breast disease, history of breast cancer in mother and sisters, age at menarche, age at menopause, use







age, marital status, education, occupation, BMI, exercise, fruit and vegetable intake, meat intake, diabetes, and







age, marital status, education, occupation, BMI, exercise, fruit and vegetable intake, meat intake, diabetes, and




94.6% Self-administered FFQ Age, sex, alcohol consumption, smoking status, coffee consumption, vegetable consumption, dairy products




82% Self-administered FFQ Sex, age, area, smoking status, weekly ethanol intake, body mass index, history of diabetes mellitus, coffee








96% Self-administered FFQ Age 8
Montague et al.
2012 [30]
UK In-person Interview Age, dialect group, interview year, education, body mass index and smoking history, green/black tea intake 8
Shafique et al.
2012 [68]
70% Self-administered FFQ Age, body mass index, smoking status, coffee consumption, alcohol intake, cholesterol level, systolic blood
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Kurahashi et al.
2008 [67]
77% Self-administered FFQ Age, area, smoking status, alcohol consumption, body mass index, marital status, and coffee, black tea, and




95% Self-administered FFQ Age, body mass index, alcohol consumption, smoking status, marital status, daily calorie intake, daily calcium








(24 h food recall and one
month food frequency)
Age, coffee, cola, total alcohol, beer, wine, spirits, smoking status, pack-years smoking, body mass index, highest







Age, marital status, education, occupation, BMI, exercise, fruit and vegetable intake, meat intake, diabetes, and






Self-administered FFQ Age, area, smoking, ethanol intake, rice intake, soy bean paste soup, and coffee intake, pickled vegetable intake




72.5% Self-administered FFQ Sex, sex-specific age, city, radiation dose, sex-specific smoking habits, and education level. 6
Galanis et al.
1998 [42]
95% Self-administered FFQ Age, years of education, Japanese place of birth, and gender. Analyses among men were also adjusted for
cigarette smoking and alcohol intake status
8
Goldbohm
et al. 1996 [59]
72% Self-administered FFQ Benign breast disease, history of breast cancer in mother and sisters, age at menarche, age at menopause, use of
oral contraceptives, age at first birth, parity, body mass index, smoking status, education, and intakes of energy,
fat, and alcohol
7

















Figure 2 Relative risk estimates of breast cancer per 3 cups increase in tea consumption.
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http://www.biomedcentral.com/1471-2407/14/197regions, and type of tea, showed no significant associa-
tions with risk of cancer.
The results of heterogeneity test suggested that most
pooled effects had mild heterogeneity. However, moder-
ate heterogeneity was seen in studies on liver cancer.
Sensitivity analysis performed by omitting one study at a
time, identified the main source of heterogeneity as the
study by Inoue et al. [64], which included hepatitis C
and B virus positive patients while the other three stud-
ies did not. After excluding this study, the overall RR
was 0.86 (95% CI, 0.75-0.99) with a mild heterogeneity
(P = 0.30, I2 = 17.1%), which suggests a preventive effect
of tea drinking for liver cancer. However, large prospect-
ive studies are still needed to verify this preventive
effect.
Eleven previous meta-analyses have evaluated the as-
sociation between green tea or black tea intake and the
risk of the five selected cancers [12-16,70-75]. Of these
earlier meta-analyses, three focused on breast cancer,
three on colorectal cancer, three on stomach cancer, one
on primary liver cancer, and one on prostate cancer. All
of the previous eleven meta-analyses reported the sum-
marized RR/OR for the highest tea consumption level
relative to the no tea/lowest level. In nine of the meta-
analyses that examine the association between green tea
consumption and cancer risk, three studies presented an
overall statistically significant inverse association be-
tween green tea consumption and cancer risk when they
included both cohort and case–control studies in the
meta-analysis. The summarized ORs of these three stud-
ies were 0.82 (95% CI, 0.70-0.96) and 0.86 (95% CI, 0.74-1.00) for stomach cancer and 0.82 (95% CI, 0.69 -0.98)
for colorectal cancer [71,72,75]. Among the eleven meta-
analyses, seven studies reported an inverse association
between green tea consumption and cancer risk from
the summarized results of case–control studies. How-
ever, none of the studies indicated a statistically signifi-
cant green tea-cancer risk association from a meta-
analysis of prospective cohort studies only. These earlier
results from prospective studies were consistent with
our present meta-analysis. For a concise comparison, we
have presented the pooled RRs of previous studies and
our study in Table 3.
Among the three meta-analyses examing the relation-
ship between black tea consumption and cancer risk,
Sun et al. presented conflicting results across cohort
studies and case–control studies for breast cancer risk
[73]. The pooled RR for prospective cohort studies was
1.15 (95% CI, 1.02 to 1.31), while the pooled RR for
case–control studies was 0.91 (95% CI, 0.84 to 0.98).
Our meta-analysis also found a positive association be-
tween black tea consumption and the risk of breast can-
cer in a subgroup analysis. The summarized RR was 1.18
(95% CI, 1.05-1.32) with an increment of three cups
black tea intake per day. Association of black tea con-
sumption with breast cancer risk is biologically plausible.
Black tea intake has been positively associated the estro-
gen levels, and experimental studies have established
that estrogen is a strong promoter of mammary carcino-
genesis [76]. Wu et al. reported that the levels of circu-
lating estrogens were higher in black tea drinkers than
in non-tea drinkers [77], and Larsson et al. reported that
Figure 3 Relative risk estimates of colorectal cancer per 3 cups increase in tea consumption.
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http://www.biomedcentral.com/1471-2407/14/197black tea consumption was positively associated with the
risk of ER+/PR + breast cancer, suggesting a possible car-
cinogenic role involving sex hormones [61].
Of the three meta-analyses exploring the association
between tea consumption and colorectal cancer risk,
Zhang et al. [74] found a positive association between
tea and colorectal cancer (RR 1.28; 95% CI, 1.02-1.61)
for tea consumption greater than four cups. Our pooledRR was 0.98 (95% CI, 0.93-1.03) with an increment of
three cups black tea intake per day. These differing re-
sults could be attributed to the calculation using differ-
ent increment cups per day. We concluded that drinking
three cups more per day does not increase the risk of
colorectal cancer while Zhang et al. concluded that
drinking four cups increment per day might be a risk
factor for colon cancer. In addition, Zhang et al. also
I-squared=52.5%, p=0.10)
Figure 4 Relative risk estimates of liver cancer per 3 cups increase in tea consumption.
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http://www.biomedcentral.com/1471-2407/14/197reported that the risk of colon cancer did not increase
with a 250 g/day increment of tea consumption either in
men (RR, 1.03; 95% CI, 0.96-1.09) or women (RR, 1.03;
95% CI, 0.99-1.08); this is consistent with our current
meta-analysis. Zhang et al. attributed the observed posi-
tive association to chance.
It is notable that most epidemiological evidence for
the inverse association between tea intake and cancer
risk has come from retrospective case–control studies.
Because information in case–control studies is collected
after cancer is diagnosed, it reflects the past exposure
history based on recall; therefore, recall bias is inevitable
and cannot be ignored. This bias may partly explain the
difference in the findings between prospective studies
and retrospective case–control studies. Given the limita-
tions of case–control studies, the conclusion that teaFigure 5 Relative risk estimates of prostate cancer per 3 cups increasconsumption has an inverse association with cancer risk
is not convincing.
When compared with previous meta-analyses, our
meta-analysis has several strengths. First, we assessed
the association of tea consumption with five major can-
cers. Second, only prospective studies were included in
the meta-analysis, which greatly reduces the likelihood
of selection and recall biases. Third, the dose–response
analysis included a wide range of tea consumption,
which allows a concrete and quantitative assessment of
the dose–response relationship between tea intake and
cancer risk.
However, several potential limitations of our meta-
analysis must be considered when interpreting the re-
sults. First, the temperature of tea is an important con-
founding factor when assessing the association betweene in tea consumption.
I-squared=40.6%, p=0.15)
Figure 6 Relative risk estimates of stomach cancer per 3 cups increase in tea consumption.
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http://www.biomedcentral.com/1471-2407/14/197tea drinking and cancer risk. However, we could not
analyze the effect of this factor because only one study
reported the relationship between iced or hot tea and
cancer; this study reported no significant association
were observed between iced or hot tea and gastric can-
cers. Second, the methods of data collection differed
across the included studies. Most of the studies assessed
the exposure of the tea consumption via food frequency
questionnaire, and the response rate varied among these
studies. As is known, people in different countries have
different traditions of tea consumption or drinking style,
which presents difficulties in assessing tea consumption
amounts accurately. In addition, people from the same
country may also have different habits of drinking tea,
such as strong or weak tea. In addition, tea consumption
level is mostly assessed as the number of cups of tea
consumed daily or weekly. However, cup size may vary
considerably for different countries or areas and the dry
tea leaves brewed in each cup may also be different. The
cut-offs for the highest consumption level varied across
different studies. Therefore, there might be some inevit-
able measurement errors and possible uncontrolled con-
founding factors when assessing tea consumption; this
could prevent the detection of a modest association be-
tween tea consumption and cancer risk. However, we
endeavoured to decrease these errors by unifying the
unit of measurement and using a similar standard to cal-
culate daily tea consumption. We also performed sensi-
tivity analyses by removing the studies that did not
report tea consumption as cups and performed subgroup
analyses by geographic region, especially China and
Japan (see Table 2). Third, we had no information about
the family history of certain cancers in the primary ag-
gregate results. Genetic factors play an important role inthe development of cancers. Some genetic factors may
increase the susceptibility to cancer, and certain poly-
morphisms in genes that are responsible for metabolis-
ing tea may have a role in the tea-cancer association.
Fourth, a meta-analysis is unable to account for con-
founding factors inherent in the original studies. Al-
though major potential confounders, including age, sex,
alcohol, and smoking had been adjusted in most in-
cluded studies, residual or unknown confounding cannot
be excluded as a potential explanation for the observed
findings. It is known that alcohol and smoking are im-
portant potential confounding factors. For example,
people in China who drink tea frequently are more likely
to drink more alcohol or smoke. The interplay of these
factors, tea, alcohol, and smoking, could not be detected
because of limited data. Most of the included studies did
not provide the numbers for case and non-case popula-
tion at each level of tea consumption; therefore, based
on the available data, analyses among non-smokers and
non-alcohol drinkers could not be conducted. Addition-
ally, not all studies adjusted for these confounding
factors. For breast cancer, the menopausal status of
women was an important confounding factor. However,
according to our subgroup analysis on pre-menopausal
(RR, 0.96; 95% CI, 0.79-1.18) and post-menopausal (RR,
1.12; 95% CI, 0.96-1.30) women, there were no sig-
nificant risk associations between tea consumption and
pre-menopausal or post-menopausal breast cancer. Con-
sidering only three studies were available for this sub-
group analysis, the results may be because of limited
sample size. Thus, menopausal status could be another
effect modifier for breast cancer, and further studies are
needed to discuss the confounding effect of this factor





















































































































Figure 7 Dose–response relations between tea consumption and relative risks of breast, colorectal, stomach, prostate cancer.
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Table 2 Subgroup analysis of cancer risk for an increment of three cup tea consumption by gender, tea type and
geographic region
Subgroup Breast Stomach Liver Prostate
N Pooled RR (95% CI) N Pooled RR (95% CI) N Pooled RR (95% CI) N Pooled RR (95% CI)
By gender
Male - - 2 1.20 (0.72-2.01) - - 6 1.02 (0.96-1.09)
Female 15 1.02 (0.98-1.05) 3 0.88 (0.80-0.98) 1 0.65 (1.30-1.43) - -
By menopausal status
Pre-menopausal 2 0.96 (0.79-1.18) - - -
Post-menopausal 3 1.12 (0.96-1.30) - - -
By tea type
Green tea 4 0.97 (0.90-1.06) 4 0.99 (0.94-1.05) 3 0.93 (0.75-1.17) 4 0.99 (0.88-1.11)
Black tea 4 1.18 (1.05-1.32) 1 0.94 (0.72-1.22) - - 3 0.99 (0.90-1.09)
By geographic region
Europe 6 1.05 (0.96-1.15) 1 0.94 (0.72-1.22) - - 2 1.07 (0.90-1.27)
Asian 4 0.98 (0.90-1.06) 4 0.99 (0.87-1.12) 4 0.91 (0.74-1.12) 4 1.00 (0.90-1.12)
China 1 1.25 (0.71-2.19) 1 0.73 (0.45-1.17) 1 0.65 (0.30-1.43) - -
Japan 3 0.97 (0.89-1.05) 3 1.01 (0.86-1.14) 3 0.90 (0.80-1.01) 3 0.99 (0.88-1.11)
North America 5 1.00 (0.94-1.07) - - - - 1 0.96 (0.79-1.17)
Subgroup Colon Rectal Colorectal
N Pooled RR (95% CI) N Pooled RR (95% CI) N Pooled RR (95% CI)
By gender
Male 6 1.00 (0.90-1.11) 5 0.96 (0.83-1.11) 6 0.98 (0.90-1.07)
Female 6 1.02 (0.92-1.14) 2 0.93 (0.78-1.10) 6 0.99 (0.90-1.09)
By tea type
Green tea 4 1.01 (0.93-1.09) 3 1.00 (0.90-1.12) 5 1.00 (0.94-1.07)
Black tea 1 0.86 (0.45-1.66) 1 1.76 (0.77-4.02) 2 0.99 (0.86-1.14)
By geographic region
Europe 3 1.02 (0.84-1.24) 3 0.92 (0.77-1.10) 4 0.96 (0.88-1.04)
Asian 5 1.00 (0.93-1.08) 4 0.99 (0.89-1.10) 6 0.99 (0.93-1.06)
China 1 0.88 (0.58-1.33) 1 0.78 (0.47-1.30) 2 0.83 (0.64-1.06)
Japan 4 1.01 (0.93-1.09) 3 1.00 (0.90-1.12) 4 1.01 (0.94-1.07)
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Figure 8 Funnel plot of log relative risk vs standard error of log relative risks.
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Table 3 omparison of findings of the present dose–response meta-analysis with those reported in previous meta-analysis
Reference Tea type Previous review* Present review#
Cohort study Case–control study Over all
N Pooled RR (95% CI) N Pooled OR (95% CI) N Pooled RR (95% CI) Tea type N Pooled RR (95% CI)
Breast cancer
Ogunleye et al. 2010 Green tea 2 0.85 (0.65-1.12) 5 0.81 (0.75-0.88) 7 0.81 (0.75-0.88) Tea 15 1.02 (0.98-1.06)
Sun et al. 2006 Green tea 3 0.85 (0.66-1.09) 1 0.47 (0.26-0.85) 4 0.78 (0.61-0.98) Green tea 4 0.97 (0.90-1.06)
Sun et al. 2006 Black tea 5 1.15 (1.02-1.31) 8 0.91 (0.84-0.98) 13 0.98 (0.88-1.09) Black tea 4 1.18 (1.05-1.32)
Seely et al. 2005 Green tea 3 0.89 (0.71-1.10) 2 0.44 (0.14-1.31) - -
Colorectal cancer
Wang et al. 2012 Green tea - - 13 0.95 (0.81-1.11) - - Tea 15 0.98 (0.93-1.03)
Sun et al. 2006 Green tea 4 0.97 (0.82-1.16) 4 0.74 (0.63-0.86) 8 0.82 (0.69-0.98) Green tea 5 1.00 (0.94-1.07)
Sun et al. 2006 Black tea 7 1.02 (0.78-1.34) 13 0.98 (0.84-1.15) 20 0.99 (0.87-1.13) Black tea 2 0.99 (0.86-1.14)
Zhang et al. 2010 Tea 13 1.28 (1.02-1.61) - - 13 1.28 (1.02-1.61)
Liver cancer
Sing et al. 2011 Tea 7 0.84 (0.69-1.02) 6 0.86 (0.44-1.14) 11 0.77 (0.57-1.03) Tea Green tea 4 0.93 (0.75-1.17)
3 0.93 (0.75-1.17)
Prostate cancer
Zheng et al. 2011 Green tea 4 1.00 (0.66-1.53) 3 0.43 (0.25-0.73) 7 0.72 (0.45-1.15) Tea 7 1.00 (0.87-1.15)
Zheng et al. 2011 Black tea Prospective: 3 0.83 (0.63-1.08) 6 1.07 (0.78-1.48) 11 0.99 (0.82-1.20) Green tea 4 0.99 (0.88-1.11)
Retrospective: 2 1.04 (0.73-1.50) Black tea 3 0.99 (0.90-1.09)
Stomach cancer
Kang et al. 2010 Green tea 7 1.03 (0.92-1.16) 11 0.74 (0.63-0.86) 18 0.86 (0.74-1.00) Tea 5 0.97 (0.92-1.02)
Myung et al. 2009 Green tea 7 1.04 (0.93-1.17) 8 0.73 (0.64-0.83) 15 0.82 (0.70-0.96) Green tea 4 0.99 (0.94-1.05)
Zhou et al. 2008 Green tea 4 1.56 (0.93-2.60) HCC:4 1.12 (0.70-1.77) 14 0.98 (0.77-1.24) Black tea 1 0.94 (0.72-1.22)
PCC:6 0.67 (0.49-0.92)
HCC: Hospital based case–control PCC: population based case–control N: number of studies included.
*Pooled results between highest consumption level and non/lowest drinker.
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http://www.biomedcentral.com/1471-2407/14/197inevitable problem in systematic reviews and meta-
analyses. However, the results of publication bias ana-
lysis showed that there was no significant evidence of
publication bias in studies on breast and colorectal can-
cer. The limited number of included studies precludes
us from conducting publication bias analyses for liver,
prostate, or stomach cancer.
Conclusion
There is insufficient information from epidemiologic
studies to support the suggestion that tea intake plays a
role in the prevention of cancer. Randomized controlled
trials and large prospective cohort studies are needed to
further explore this association.
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